

European Patent Office

Office européen des brevets



EP 0 708 179 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:22.12.2004 Bulletin 2004/52 (51) Int Cl.⁷: **C12N 15/16**, C07K 14/605, A61K 38/26

(11)

- (21) Application number: 95307299.8
- (22) Date of filing: 13.10.1995

(54) Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

Glucagon-ähnliche insulinotrope Peptid-Analoge, Zusammensetzungen und Verwendungsverfahren Analogues de peptides insulinotropes de type glucagon, compositions et méthodes d'utilisation

(84)	4) Designated Contracting States:		 Dimarchi, Richard D. 		
	AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT	Carmel, Indiana 46033 (US)			
	SE	 Kriauciunas, Aidas V. 			
	Designated Extension States:		Indianapolis, Indiana 46254 (US)		
	LT LV SI	•	Smiley, David L.		
			Greenfield, Indiana 4614	40 (US)	
(30)	(30) Priority: 18.10.1994 US 324960		Stucky, Russell D.		
. ,			Indianapolis, Indiana 46	227 (US)	
(43)	Date of publication of application:				
. ,	24.04.1996 Bulletin 1996/17	(74)	Representative: Kent, Lir	ndsey Ruth et al	
			Eli Lilly and Company L	imited	
(60)	Divisional application:		Lilly Research Centre		
	02000257.2 / 1 227 151		Erl Wood Manor		
			Sunninghill Road		
(73)	Proprietor: ELI LILLY AND COMPANY		Windlesham, Surrey GU20 6PH (GB)		
	Indianapolis, Indiana 46285 (US)				
		(56)	References cited:		
(72)	Inventors:		EP-A- 0 658 568	WO-A-91/11457	
•	Chen, Victor John		WO-A-92/18531		
	Indianapolis, Indiana 46140 (US)				

0 708 179 B1 ۵

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 20(4) European Patent Opposition)

Find authenticated court documents without watermarks at docketalarm.com.

Description

5

DOCKET

[0001] The present invention relates to organic and peptide chemistry as applied to pharmaceutical research and development. The invention provides novel peptide derivatives and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes.

- **[0002]** Endocrine secretions of pancreatic islets are regulated by complex control mechanisms driven not only by blood-borne metabolites such as glucose, amino acids, and catecholamines, but also by local paracrine influences. The major pancreatic islet hormones, glucagon, insulin and somatostatin, interact with specific pancreatic cell types (A, B, and D cells, respectively) to modulate the secretory response. Although insulin secretion is predominantly con-
- trolled by blood glucose levels, somatostatin inhibits glucose-mediated insulin secretion. In addition to inter-islet paracrine regulation of insulin secretion, there is evidence to support the existence of insulinotropic factors in the intestine. This concept originates from observations that glucose taken orally is a much more potent stimulant of insulin secretion than is a comparable amount of glucose given intravenously.
- [0003] The human hormone glucagon is a 29-amino acid hormone produced in pancreatic A-cells. The hormone belongs to a multi-gene family of structurally related peptides that include secretin, gastric inhibitory peptide, vasoactive intestinal peptide and glicentin. These peptides variously regulate carbohydrate metabolism, gastrointestinal mobility and secretory processing. However, the principal recognized actions of pancreatic glucagon are to promote hepatic glycogenolysis and glyconeogenesis, resulting in an elevation of blood sugar levels. In this regard, the actions of glucagon are counter regulatory to those of insulin and may contribute to the hyperglycemia that accompanies Diabetes mellitus (Lund, P.K., et al., Proc. Natl. Acad. Sci. U.S.A., 79:345-349 (1982)).
- mellitus (Lund, P.K., *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, <u>79</u>:345-349 (1982)).
 [0004] When glucagon binds to its receptor on insulin producing cells, cAMP production increases which in turn stimulates insulin expression (Korman, L.Y., *et al.*, *Diabetes*, <u>34</u>:717-722 (1985)). Moreover, high levels of insulin down-regulate glucagon synthesis by a feedback inhibition mechanism (Ganong, W.F., *Review of Medical Physiology*, Lange Publications, Los Altos, California, p. 273 (1979)). Thus, the expression of glucagon is carefully regulated by insulin,
- and ultimately by serum glucose levels.
 [0005] Preproglucagon, the precursor form of glucagon, is encoded by a 360 base pair gene and is processed to form proglucagon (Lund, *et al., Proc. Natl. Acad. Sci. U.S.A.* <u>79</u>:345-349 (1982)). Patzelt, *et al.* (*Nature,* <u>282</u>:260-266 (1979)) demonstrated that proglucagon is further processed into glucagon and a second peptide. Later experiments demonstrated that proglucagon is cleaved carboxyl to Lys-Arg or Arg-Arg residues (Lund, P.K., *et al.,* Lopez L.C., *et*
- 30 al., Proc. Natl. Acad. Sci. U.S.A., 80:5485-5489 (1983), and Bell, G.I., et al., Nature 302:716-718 (1983)). Bell, G.I., et al., also discovered that proglucagon contained three discrete and highly homologous peptide regions which were designated glucagon, glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2). Lopez, et al., demonstrated that GLP-1 was a 37 amino acid peptide and that GLP-2 was a 34 amino acid peptide. Analogous studies on the structure of rat preproglucagon revealed a similar pattern of proteolytic cleavage at Lys-Arg or Arg-Arg residues,
- ³⁵ resulting in the formation of glucagon, GLP-1, and GLP-2 (Heinrich, G., *et al.,' Endocrinol.*, <u>115</u>:2176-2181 (1984)). Finally, human, rat, bovine, and hamster sequences of GLP-1 have been found to be identical (Ghiglione, M., *et al., Diabetologia*, <u>27</u>:599-600 (1984)).

[0006] The conclusion reached by Lopez, *et al.*, regarding the size of GLP-1 was confirmed by studying the molecular forms of GLP-1 found in the human pancreas (Uttenthal, L.O., *et al. J. Clin. Endocrinol. Metabol.*, <u>61</u>:472-479 (1985)).

40 Their research showed that GLP-1 and GLP-2 are present in the pancreas as 37 and 34 amino acid peptides respectively.

[0007] The similarity between GLP-1 and glucagon suggested to early investigators that GLP-1 might have biological activity. Although some investigators found that GLP-1 could induce rat brain cells to synthesize cAMP (Hoosein, N. M., *et al., Febs Lett.* <u>178</u>:83-86 (1984)), other investigators failed to identify any physiological role for GLP-1 (Lopez,

- L.C., *et al. supra*). The failure to identify any physiological role for GLP-1 caused some investigators to question whether GLP-1 was in fact a hormone and whether the relatedness between glucagon and GLP-1 might be artifactual.
 [0008] It has now been shown that biologically processed forms of GLP-1 have insulinotropic properties and may delay gastric emptying. GLP-1(7-34) and GLP-1(7-35) are disclosed in U.S. Patent No: 5,118,666. GLP-1(7-37) is disclosed in U.S. Patent No: 5,120,712.
- 50 [0009] Variants and analogs of GLP-1 are known in the art. These variants and analogs include, for example, GLP-1(7-36), Gln⁹-GLP-1(7-37), D-Gln⁹-GLP-1(7-37), acetyl-Lys⁹-GLP-1(7-37), Thr¹⁶-Lys¹⁸-GLP-1(7-37), and Lys¹⁸-GLP-1(7-37). Derivatives of GLP-1 include, for example, acid addition salts, carboxylate salts, lower alkyl esters, and amides (see, e.g., WO91/11457). Generally, the various disclosed forms of GLP-1 are known to stimulate insulin secretion (insulinotropic action) and cAMP formation (see, e.g., Mojsov, S., Int. J. Peptide Protein Research, 40:333-343 (1992)).
- ⁵⁵ **[0010]** EP A 0658568 published after the priority date of the present application relates to glucagon- like peptide-1 molecules having a modified histidine functionality at the 7-position.

[0011] More importantly, numerous investigators have demonstrated a predictable relationship between various *in vitro* laboratory experiments and mammalian, especially human, insulinotropic responses to exogenous administration

EF U / UO I / 9 DI

of GLP-1, GLP-1(7-36) amide, and GLP-1(7-37) acid (see, e.g., Nauck, M.A., et al., Diabetologia, <u>36</u>:741-744 (1993); Gutniak, M., et al., New England J. of Medicine, <u>326</u>(20):1316-1322 (1992); Nauck, M.A., et al., J. Clin. Invest., <u>91</u>: 301-307 (1993); and Thorens, B., et al., Diabetes, <u>42</u>:1219-1225 (1993)).

- [0012] The fundamental defects responsible for causing hyperglycemia in mature onset diabetes include impaired secretion of endogenous insulin and resistance to the effects of insulin by muscle and liver tissue (Galloway, J.S., *Diabetes Care*, <u>13</u>:1209-1239, (1990)). The latter defect results in excess glucose production in the liver. Thus, whereas a normal individual releases glucose at the rate of approximately 2 mg/kg/minute, a patient with mature onset diabetes releases glucose at a rate exceeding 2.5 mg/kg/minute, resulting in a net excess of at least 70 grams of glucose per 24 hours.
- 10 [0013] Because there exists exceedingly high correlations between hepatic glucose production, fasting blood glucose levels, and overall metabolic control as indicated by glycohemoglobin measurements (Galloway, J.A., *supra*; and Galloway, J.A., *et al.*, *Clin. Therap.*, <u>12</u>:460-472 (1990)), it is readily apparent that control of fasting blood glucose is essential for achieving overall normalization of metabolism sufficient to prevent hyperglycemic complications. Since existing insulin therapies rarely normalize hepatic glucose production without producing significant hyperinsulinemia
- and hypoglycemia (Galloway, J.A., and Galloway, J.A., *et al.*, supra) alternative approaches are needed. Therapy based on administration of GLP-1 analogs is one such approach and is an object of the present invention.
 [0014] Presently, therapy involving the use of GLP-1 type molecules has presented a significant problem because the serum half-life of such peptides is quite short. For example, GLP-1(7-37) has a serum half-life of only 3 to 5 minutes. Presently, the activity of dipeptidyl-peptidase IV (DPP IV) is believed to readily inactivate GLP-1(7-37) in addition to
- ²⁰ rapid absorption and clearance following parenteral administration. Thus, there exists a critical need for biologically active GLP-1(7-37) analogs that possess extended pharmacodynamic profiles following parenteral administration. [0015] Accordingly, the primary object of this invention is to provide novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics but also produce other beneficial insulinotropic responses. The compounds of the present invention persist in the serum for longer periods than native GLP-1(7-37) either by showing
- ²⁵ resistance to DPP IV or by being absorbed and cleared slower than native GLP-1(7-37) following parenteral administration. Most surprisingly, some compounds of the present invention demonstrated a synergistic effect as individual alterations to GLP-1(7-37) failed to add-up to the biological performance of compounds that contained all of the alterations.

[0016] The present invention provides compounds of the general formula:

30

35

R¹-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Xaa-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-R³ (Formula 1)

40 wherein

 R^1 is selected from 4-imidazopropionyl (des-amino-histidyl), 4-imidazoacetyl, or 4-imidazo- α , α dimethyl-acetyl; R^2 is selected from C_6 - C_{10} unbranched acyl, or is absent;

 R^3 is selected from Gly-OH or NH₂; and,

45 Xaa is Lys or Arg,

DOCKET

with the proviso when \mathbb{R}^1 is 4-imidazopropionyl and Xaa is Lys, \mathbb{R}^2 is selected from \mathbb{C}_6 - \mathbb{C}_{10} unbranched acyl. **[0017]** The present invention also provide pharmaceutical compositions comprising a compound of the present invention in combination with a pharmaceutically acceptable carrier diluent, or excipient. The present invention further

vention in combination with a pharmaceutically acceptable carrier, diluent, or excipient. The present invention further
 provides for the use of a compound of the present invention for treating non-insulin dependant diabetes mellitus in a mammal in need of such treatment comprising administering an effective amount of a compound of the present invention to said mammal.

[0018] In one embodiment, the present invention provides analogs of naturally-occuring GLP-1(7-37) that arise from adding various R groups via a peptide bond to the amino terminus of the peptide portion of Formula 1. Optionally,

⁵⁵ further compounds of the invention are made by acylating the epsilon amino group of the Lys³⁴ residue and by making limited amino acid substitutions at position 26 or by altering the carboxy terminus. Therefore, preparing the polypeptide backbone of Formula 1 is a logical first step when preparing compounds of the present invention.

[0019] It should be noted that this specification uses the nomenclature scheme that has developed around processed

EF U / UO I / 9 DI

forms of GLP-1. In this scheme, the amino terminus of the known GLP-1(7-37)OH has been assigned number 7 and the carboxy terminus number 37. Therefore, the first Ala residue of Formula 1 corresponds to residue 8 of GLP-1(7-37) OH. Likewise Xaa in Formula 1 corresponds to residue 26 of GLP-1(7-37)OH and so forth.

[0020] Given the sequence information herein disclosed and the state of the art in solid phase protein synthesis, the
 protein portion of Formula 1 can be prepared via chemical synthesis. Also, recombinant DNA techniques may be used to express the protein backbone of Formula 1.

[0021] The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found in general texts in the area such as Dugas, H. and Penney, C., <u>Bioorganic Chemistry</u> (1981) Springer-Verlag, New York, pgs. 54-92, Merrifield, J.M., *Chem. Soc.*, <u>85</u>:2149 (1962), and Stewart and Young, *Solid Phase Peptide Synthesis*, pp. 24-66, Freeman (San Francisco, 1969).

¹⁰ pp. 24-66, Freeman (San Francisco, 1969). [0022] For example, the protein portion of Formula 1 may be synthesized by solid-phase methodology utilizing a 430A peptide synthesizer (PE-Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster City, CA 94404) and synthesis cycles supplied by PE-Applied Biosystems. Boc amino acids and other reagents are commercially available from PE-Applied Biosystems and other chemical supply houses. Sequential Boc chemistry using double couple protocols are

¹⁵ applied to the starting p-methyl benzhydryl amine resins for the production of C-terminal carboxamides. For the production of C-terminal acids, the corresponding PAM resin is used. Asn, Gln, and Arg are coupled using preformed hydroxy benzotriazole esters. The following side chain protecting groups may be used:

Arg, Tosyl

Asp, cyclohexyl Glu, cyclohexyl Ser, Benzyl Thr, Benzyl Tyr, 4-bromo carbobenzoxy

25

30

50

DOCKET

20

[0023] Boc deprotection may be accomplished with trifluoroacetic acid in methylene chloride. Following completion of the synthesis the peptides may be deprotected and cleaved from the resin with anhydrous hydrogen fluoride (HF) containing 10% meta-cresol. Cleavage of the side chain protecting group(s) and of the peptide from the resin is carried out at -5°C to 5°C, preferably on ice for 60 minutes. After removal of the HF, the peptide/resin is washed with ether, and the peptide extracted with glacial acetic acid and lyophilized.

- **[0024]** The preparation of protected, unprotected, and partially protected GLP-1 molecules has been described in the art. See U.S. Pat. No. 5,120,712 and 5,118,666 and Orskov, C., *et al., J. Biol. Chem.,* <u>264</u>(22):12826-12829 (1989) and WO 91/11457 (Buckley, D.I., *et al.,* published August 8, 1991).
- [0025] Likewise, the state of the art in molecular biology provides the ordinarily skilled artisan another means by which the protein portion of Formula 1 can be obtained. Although it may be produced by solid phase peptide synthesis or recombinant methods, recombinant methods may be preferable because higher yields are possible. The basic steps in recombinant production are:

a) isolating a natural DNA sequence encoding GLP-1 or constructing a synthetic or semisynthetic DNA coding
 sequence for GLP-1,

b) placing the coding sequence into an expression vector in a manner suitable for expressing proteins either alone or as a fusion proteins,

- c) transforming an appropriate eukaryotic or prokaryotic host cell with the expression vector,
 - d) culturing the transformed host cell under conditions that will permit expression of a GLP-1 intermediate, and
 - e) recovering and purifying the recombinantly produced protein.

[0026] As previously stated, the coding sequences may be wholly synthetic or the result of modifications to the larger, native glucagon-encoding DNA. A DNA sequence that encodes preproglucagon is presented in Lund, *et al., Proc. Natl. Acad. Sci. U.S.A.* <u>79</u>:345-349 (1982) and may be used as starting material in the semisynthetic production of the compounds of the present invention by altering the native sequence to achieve the desired results.

⁵⁵ **[0027]** Synthetic genes, the *in vitro* or *in vivo* transcription and translation of which results in the production of the protein portion of Formula 1, may be constructed by techniques well known in the art. Owing to the natural degeneracy of the genetic code, the skilled artisan will recognize that a sizable yet definite number of DNA sequences may be constructed, all of which encode the polypeptide of Formula 1.

EF U / UO 1/9 DI

[0028] The methodology of synthetic gene construction is well known in the art. *See* Brown, *et al.* (1979) *Methods in Enzymology*, Academic Press, N.Y., Vol. 68, pgs. 109-151. DNA sequences that encode the protein backbone of Formula 1 can be designed based on the amino acid sequences herein disclosed. Once designed, the sequence itself may be generated using conventional DNA synthesizing apparatus such as the Model 380A or 380B DNA synthesizers (DE Applied Discutteres, N.S., Vol. 68, pgs. 250 Lincels, Center Drive, Fester City, CA 04404).

- ⁵ (PE-Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster City, CA 94404). [0029] To effect expression of the polypeptide of Formula 1, one inserts the engineered synthetic DNA sequence in any one of many appropriate recombinant DNA expression vectors through the use of appropriate restriction endonucleases. See generally Maniatis et al. (1989) Molecular Cloning; A Laboratory Manual, Cold Springs Harbor Laboratory Press, N.Y., Vol. 1-3. Restriction endonuclease cleavage sites are engineered into either end of the GLP-1 intermediate-
- ¹⁰ encoding DNA to facilitate isolation from, and integration into, known amplification and expression vectors. The particular endonucleases employed will be dictated by the restriction endonuclease cleavage pattern of the parent expression vector to be employed. The choice of restriction sites are chosen so as to properly orient the coding sequence with control sequences to achieve proper in-frame reading and expression of the protein of interest. The coding sequence must be positioned so as to be in proper reading frame with the promoter and ribosome binding site of the expression vector, both of which are functional in the host cell in which the protein is to be expressed.
- expression vector, both of which are functional in the host cell in which the protein is to be expressed.
 [0030] To achieve efficient transcription of the synthetic gene, it must be operably associated with a promoter-operator region. Therefore, the promoter-operator region of the synthetic gene is placed in the same sequential orientation with respect to the ATG start codon of the synthetic gene.
 - [0031] A variety of expression vectors useful for transforming prokaryotic and eukaryotic cells are well known in the
- art. See The Promega Biological Research Products Catalogue (1992) (Promega Corp., 2800 Woods Hollow Road, Madison, WI, 53711-5399); and The Stratagene Cloning Systems Catalogue (1992) (Stratagene Corp., 11011 North Torrey Pines Road, La Jolla, CA, 92037). Also, U.S. Patent No. 4,710,473 describes circular DNA plasmid transformation vectors useful for expression of exogenous genes in *E. coli* at high levels. These plasmids are useful as transformation vectors in recombinant DNA procedures and
- 25

35

DOCKET

- (a) confer on the plasmid the capacity for autonomous replication in a host cell;
- (b) control autonomous plasmid replication in relation to the temperature at which host cell cultures are maintained;
- ³⁰ (c) stabilize maintenance of the plasmid in host cell populations;
 - (d) direct synthesis of a protein prod. indicative of plasmid maintenance in a host cell population;
 - (e) provide in series restriction endonuclease recognition sites unique to the plasmid; and
 - (f) terminate mRNA transcription.

These circular DNA plasmids are useful as vectors in recombinant DNA procedures for securing high levels of expression of exogenous genes.

- ⁴⁰ **[0032]** Having constructed an expression vector for the protein of Formula 1, the next step is to place the vector into a suitable cell and thereby construct a recombinant host cell useful for expressing the polypeptide. Techniques for transforming cells with recombinant DNA vectors are well known in the art and may be found in such general references as Maniatis, *et al. supra.* Host cells made be constructed from either eukaryotic or prokaryotic cells.
- [0033] Prokaryotic host cells generally produce the protein at higher rates and are easier to culture. Proteins which are expressed in high-level bacterial expression systems characteristically aggregate in granules or inclusion bodies which contain high levels of the overexpressed protein. Such protein aggregates typically must be solubilized, denatured and refolded using techniques well known in the art. See Kreuger, *et al.* (1990) in *Protein Folding*, Gierasch and King, eds., pgs 136-142, American Association for the Advancement of Science Publication No. 89-18S, Washington, D.C.; and U.S. Patent No. 4,923,967.
- ⁵⁰ **[0034]** Having preparing the polypeptide backbone of Formula 1, an imidazole, as defined above in the "Summary of the Invention," is added to the amino terminus to produce various embodiments of the present invention. Coupling the imidazolic group to the polypeptide of Formula 1 is accomplished by synthetic chemical means. Because all of the various organic groups contemplated in this invention contain a carboxylic acid, the imidazolic group can be added by solid phase protein synthesis analogous to adding an amino acid to the N-terminus of a polypeptide. Alternatively, an
- activated ester of the imidazolic group can be added by standard chemical reaction methods.
 [0035] Preferred imidazolic groups of the present invention are:

4-imidazopropionyl (des-amino-histidyl)

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

